Enterprise context
The company operates a network of veterinary care facilities supported by diagnostics, pharmacy, surgery, emergency services and digital engagement. The patient cannot describe symptoms or consent, while the owner is often making emotional and financially significant decisions under time pressure. This creates a duty to communicate uncertainty, alternatives, prognosis, cost and referral needs with unusual clarity.
The company is preparing for a public listing while integrating facilities and building common clinical and operating systems. Growth can create better access and specialist depth, but it can also introduce incentives for unnecessary diagnostics, inconsistent prescribing, premature procedures, weak referral, opaque packages or inadequate staffing. The Board seeks an Independent Director who will protect clinical judgment and animal welfare while bringing discipline to network economics and public-market reporting.
Board mandate
The Director will oversee clinical governance, informed owner consent, medication stewardship, diagnostic quality, surgical safety, emergency readiness, professional conduct, pricing transparency, complaints, acquisition integration and IPO assurance. The appointee must be independent of commercial pressure and capable of asking whether growth is improving clinical capability or simply increasing treatment volume.
The role includes Audit Committee responsibility for revenue recognition, packages, deposits, refunds, controlled inventory, pharmacy margins, clinician incentives, receivables, acquisition accounting and provisions for claims. The Board requires a director able to connect clinical outcomes, consumer conduct and financial evidence.
Strategic and governance responsibilities
-
Establish a clinical governance system. Define professional accountability, clinical privileges, peer review, protocol ownership, case escalation and Board reporting. Facility managers must not overrule clinical safety decisions for commercial reasons.
-
Protect informed owner consent. Require understandable diagnosis, uncertainty, options, expected cost, material risk, likely outcome and referral alternatives. Consent should be a conversation supported by records, not merely a signature.
-
Govern emergency and critical care. Review triage, staffing, equipment, oxygen, medicines, blood or referral pathways, monitoring, handover and escalation. Marketing should not describe an emergency capability beyond what is continuously supportable.
-
Strengthen surgical safety. Examine patient identity, site and procedure confirmation, anaesthetic assessment, monitoring, sterile practice, implant or consumable traceability, recovery and discharge instructions.
-
Assure diagnostic integrity. Govern sample identity, equipment maintenance, calibration, image and laboratory review, external referrals, corrected reports and communication of critical results.
-
Improve medication stewardship. Review formulary, prescribing, controlled medicines, antimicrobial use, storage, expiry, dispensing, adverse events and conflicts with pharmacy economics.
-
Make pricing transparent. Require estimates, change approval, package inclusions, emergency charges, deposits, refunds and itemised records. Owners should understand material cost changes before treatment where circumstances permit.
-
Align clinician incentives. Incentives should reward clinical quality, communication, continuity, professional development and appropriate referral—not test, procedure or medicine volume alone.
-
Use outcomes and complaints to learn. Track mortality and complications by clinical context, returns, treatment changes, diagnostic corrections, owner allegations and welfare concerns. Avoid simplistic ranking that discourages difficult cases.
-
Protect records and images. Govern minimum access, owner consent, retention, corrections, sharing, research or teaching use and deletion. Personal owner information and clinical animal records require distinct handling.
-
Strengthen acquisition diligence. Review practitioner credentials, clinical incidents, claims, controlled inventory, record quality, facility safety, leases, customer complaints and owner dependence before valuation.
-
Integrate without destabilising care. Sequence credential verification, pharmacy controls, emergency pathways, systems migration, pricing, staffing and brand changes. Synergy targets must not reduce safe coverage.
-
Prepare for network-wide events. Test medicine or vaccine recall, infectious-disease cluster, oxygen or power failure, cyberattack, clinician misconduct allegation, adverse media and temporary facility closure.
-
Assure IPO metrics. Define facilities, active clinical capacity, visits, repeat care, procedures, diagnostic use, outcomes, clinician productivity, customer retention and mature-site economics without encouraging overtreatment.
Decisions expected at Board level
The Director will contribute to acquisitions, specialist-service entry, emergency capability, pharmacy and diagnostics strategy, new facility approvals, clinician partnership models, pricing architecture, technology, insurance or care plans, major claims and IPO launch readiness.
Every new service should identify clinical need, competence, staffing, referral, equipment, quality measures, consent, pricing and discontinuation arrangements. Acquisition proposals should separate sustainable clinical earnings from revenue dependent on a particular practitioner, weak controls or aggressive treatment patterns.
Clinical quality, audit and IPO readiness
The Board dashboard should include credentialing gaps; serious clinical events; anaesthetic and surgical complications; diagnostic corrections; medication exceptions; antimicrobial trends; emergency transfers; consent and price disputes; complaints; claims; clinician turnover; facility contribution; pharmacy inventory; audit findings; acquisition-integration milestones; and IPO remediation.
Clinical assurance should include record review by qualified independent professionals, case-conference evidence, pharmacy counts, diagnostic tracing, consent sampling and facility readiness drills. A clinician must be able to raise an animal-welfare or commercial-pressure concern directly to the Clinical Quality and Ethics Committee without retaliation.
Candidate profile
Candidates should bring at least 22 years of senior leadership across healthcare, veterinary services, clinical governance, diagnostics, hospital operations, pharmacy, consumer services, audit, finance or listed-company boards. Direct veterinary experience is valuable but not mandatory if the candidate has demonstrated responsibility for clinical quality and can work effectively with independent veterinary experts.
Suitable candidates may include former healthcare CEOs, medical or clinical directors, quality leaders, CFOs, risk executives, payer leaders, Audit Committee Chairs or directors experienced in healthcare network integration and IPO readiness. The candidate must protect professional judgment while understanding site economics and consumer vulnerability.
Eligibility, independence and conflicts
Active inclusion in the IICA Independent Directors Databank is mandatory. The candidate must satisfy all independence and eligibility standards applicable to an IPO-stage and subsequently listed company. Relationships involving promoters, investors, veterinary businesses, pharmaceutical or device suppliers, diagnostics providers, insurers, referral partners, auditors, lenders or transaction advisers must be disclosed.
The role may not be used to create referrals, product placement, laboratory volume, insurance distribution, property or consulting engagements. Independence must continue through listing and beyond.
First 100-day priorities
- Visit different facility formats and observe routine, surgical and emergency workflows.
- Review serious cases, complications, complaints, diagnostic corrections and medication exceptions.
- Examine clinician incentives, credentials, staffing and after-hours capability.
- Reconstruct mature and ramping facility economics after full clinical-support costs.
- Test clinical and operating metrics intended for IPO disclosure.
- Establish independent escalation standards for animal welfare, clinical conduct and owner harm.
First-year outcomes
The first year should produce stronger clinical privileges, safer procedures, transparent consent and pricing, responsible medication use, integrated acquisitions and IPO metrics that reward quality rather than treatment intensity. The company should enter public markets with animal welfare and professional independence embedded in its growth model.